What's in Ju Seok Ryu's pipeline?

Ju Seok Ryu has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Ju Seok Ryu's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ju-seok-ryu.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Ju Seok Ryu — Portfolio Competitive Intelligence Brief

Ju Seok Ryu pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Pregabalin and Oxcarbazepine	Pregabalin and Oxcarbazepine	marketed	Anticonvulsant combination; Gabapentinoid and aromatic antiepileptic drug	Alpha-2-delta calcium channel subunit (pregabalin); voltage-gated sodium channels (oxcarbazepine)	Neurology

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Ju Seok Ryu:

Cite this brief

Drug Landscape (2026). Ju Seok Ryu — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ju-seok-ryu. Accessed 2026-05-15.